Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Bon Health vs Hims & Hers

Bon Health
Graded #113

Lower grade

vs+11.299999999999997
Hims & Hers
Graded #36

Higher grade

The verdict

Hims & Hers takes it — 81/100 to 69.7/100.

Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHims & Hers +7
75
82
Dose & formulationHims & Hers +14
64
78
Clinical oversightBon Health +3
85
82
Labs & monitoringHims & Hers +25
55
80
FulfillmentHims & Hers +12
72
84
Contract termsHims & Hers +27
53
80
Bon Health · left barHims & Hers · right bar

The numbers

MetricBon HealthHims & Hers
WeighScore69.7/10081/100
GradeCB−
Scorecard rank#113#36
Semaglutide$120/mo (12-month plan, compounded)$199/mo
Tirzepatide$170/mo (12-month plan, compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Bon Health

Graded #113 · C

Strengths

  • Transparent commitment-tier pricing from $170/mo (annual) for compounded semaglutide and tirzepatide; $0 membership fee, cancel anytime
  • Physician-led: comprehensive medical review and physician-titrated dosing, not a 2-minute quiz
  • 24/7 physician support included free with your order; 1-3 day rapid dispatch
  • Licensed in all 50 states; uses 503A & 503B compounding pharmacies; brand-name Wegovy/Ozempic/Zepbound/Mounjaro also offered

Where it loses points

  • The advertised rates need a full year paid up front; billed monthly, semaglutide is $230 and the annual figure nearly doubles
  • The brand-name pages are marketing, not products — every Wegovy, Ozempic, Zepbound and Mounjaro CTA reads 'Coming Soon' and points back to the compounded version
  • Coverage is not published: a badge claims all 50 states while the weight-loss page says availability varies by state
  • The terms page returns a 404, so the refund mechanics behind the prepaid 3-, 6- and 12-month tiers cannot be read
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
Hims & Hers

Graded #36 · B−

Strengths

  • Nationwide
  • Polished app
  • Strong brand trust

Where it loses points

  • Tirzepatide pricing inconsistently disclosed
  • Industry-wide compounding scrutiny

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard